Poseida is developing cell and gene therapies. Cell therapy programs encompass both autologous and allogenic Chimeric Antigen Receptor T-cells (CAR-T) therapies. We have a collaboration with Janssen to develop allogeneic CAR-T therapies. Autologous and other cell therapy programs such as NK-cells are being developed in-house. Our gene therapy programs have demonstrated promise in correcting congenital liver diseases that often have no effective treatment other than liver transplant. Please contact us with investment inquiries.